Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma 95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy. Median progression free survival (mPFS) was 12.9 months as of the July 17, 2023 data cut-of

Related Keywords

Greece ,Athens ,Attikír ,United States ,California ,Polina Stepensky ,Gabriel Morris ,Los Angeles ,Ilya Rachman ,Mike Moyer ,Immix Biopharma Inc ,International Myeloma Working Group ,International Myeloma Society Annual Meeting ,Exchange Commission ,Nasdaq ,Nexcella Inc ,Immix Biopharma Announces ,Annual Meeting ,Overall Response Rate ,Leading Response Rate ,Hadassah Medical Organization ,Bone Marrow Transplantation ,Chief Financial Officer ,Chief Executive Officer ,Biopharma Announces ,Uniform Response ,Multiple Myeloma ,Immix Biopharma ,Orphan Drug Designation ,Tissue Specific Therapeutic ,Rare Pediatric Disease Designation ,Risk Factor ,Annual Report ,Iopharma ,Response Rates ,Clinical Data ,Therapeutic Dose ,Response Rate ,Clinical Trials ,